These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26209738)

  • 1. Key pathways in renal disease progression of experimental diabetes.
    Zoja C; Zanchi C; Benigni A
    Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv54-9. PubMed ID: 26209738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G; Macia M; Ruggenenti P
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of diabetic nephropathy: Recent progress and future perspective.
    Ahmad J
    Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets.
    Zoja C; Xinaris C; Macconi D
    Front Pharmacol; 2020; 11():586892. PubMed ID: 33519447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How I evaluate...diabetic nephropathy. First part: micro- and macroalbuminuria].
    Weekers L; Scheen AJ; Lefebvre PJ
    Rev Med Liege; 1998 Aug; 53(8):494-8. PubMed ID: 9810212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic nephropathy.
    Ritz E
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan in incipient and overt diabetic renal disease.
    Schmieder RE; Bakris G; Weir MR
    J Nephrol; 2011; 24(3):263-73. PubMed ID: 21374585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy.
    Ding D; Du Y; Qiu Z; Yan S; Chen F; Wang M; Yang S; Zhou Y; Hu X; Deng Y; Wang S; Wang L; Zhang H; Wu H; Yu X; Zhou Z; Liao Y; Chen X
    J Mol Med (Berl); 2016 Feb; 94(2):207-18. PubMed ID: 26407577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing progression along the renal disease continuum.
    Kopyt NP
    J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients].
    Zaoui P; Hannedouche T; Combe C
    Nephrol Ther; 2017 Jun; 13(6S):6S16-6S24. PubMed ID: 29463395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-diabetic renal disease in patients with type-2 diabetes mellitus.
    Yaqub S; Kashif W; Hussain SA
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):1000-7. PubMed ID: 22982913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.